DYANAVEL XR 5
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DYANAVEL XR 5 (DYANAVEL XR 5).
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
| Metabolism | Primarily hepatic via carboxylesterase 1 (CES1) to active metabolite dexmethylphenidate; further metabolism by CYP2D6 and carboxylesterases. |
| Excretion | Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%). |
| Half-life | Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect. |
| Protein binding | d-Amphetamine: ~20% bound to albumin and alpha1-acid glycoprotein; l-amphetamine: ~15% bound. |
| Volume of Distribution | Vd: 3-4 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: Approximately 100% (extended-release formulation provides prolonged absorption). |
| Onset of Action | Oral: Approximately 30-60 minutes; peak effect at 3 hours. |
| Duration of Action | Duration of effect is up to 12 hours with once-daily dosing; clinical effect lasts approximately 8-12 hours. |
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: not recommended; hemodialysis: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended. |
| Pediatric use | Children 6-12 years: initial 10 mg orally once daily; may increase by 5-10 mg weekly; maximum 30 mg/day. Children ≥13 years: same as adult dosing. |
| Geriatric use | Start at 10 mg orally once daily; titrate cautiously; monitor for cardiovascular effects and tolerance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DYANAVEL XR 5 (DYANAVEL XR 5).
| Breastfeeding | Contraindicated during breastfeeding due to amphetamine excretion into breast milk (M/P ratio ~3.8). Potential for infant stimulation, poor weight gain, and toxicity. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third trimester: Increased risk of preterm birth, low birth weight, and withdrawal symptoms. Chronic use may cause neonatal adaptation syndrome (irritability, poor feeding). |
| Fetal Monitoring |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants (including DYANAVEL XR) have a high potential for abuse and dependence, which can lead to tolerance and severe psychological dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.
| Serious Effects |
["Hypersensitivity to methylphenidate or any component of the formulation","Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI","Glaucoma","Motor tics or family history or diagnosis of Tourette's syndrome","Severe hypertension, angina, cardiac arrhythmias, or other structural cardiac abnormalities"]
| Precautions | ["Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with structural cardiac abnormalities or other serious heart problems.","Blood pressure and heart rate increases: monitor frequently.","Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, or aggressive behavior; new onset of psychotic or manic symptoms.","Seizures: may lower seizure threshold in patients with prior history or EEG abnormalities.","Prolonged erections (priapism): medical intervention required.","Peripheral vasculopathy: including Raynaud's phenomenon.","Long-term suppression of growth in children: monitor height and weight."] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, weight gain, and signs of toxicity. Fetal monitoring for intrauterine growth restriction and preterm labor. Neonatal monitoring for withdrawal symptoms. |
| Fertility Effects | Amphetamines may impair female fertility by disrupting ovulation and menstrual cycles. Limited data on male fertility; no definite effects reported. |